Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  eltrombopag olamine
Find trials that include:  Any drugs shown
Results 1-13 of 13 for your search:
Start Over
Eltrombopag Olamine in Treating Thrombocytopenia in Patients with Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2011-0319, NCI-2011-03336, NCT01428635
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 112121, NCI-2014-02104, NCT02158936
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: PrE0901, NCI-2012-01538, ELT114465, NCT01656252
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Relapsed Multiple Myeloma Undergoing Chemotherapy
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 11-373, NCI-2012-00821, NCT01484314
Lenalidomide and Eltrombopag Olamine in Treating Patients with Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2012-407, NCI-2013-01219, 115479, 12-007, RV--MDS-PI-0645, NCT01772420
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 117146, NCI-2013-02336, TRC117146, NCT01890746
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0225, NCI-2013-02252, NCT01893372
Eltrombopag Olamine and Decitabine in Treating Patients with Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0590, NCI-2014-01276, NCI-2014-00856, NCT02010645
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Phase: Phase II
Type: Supportive care
Age: 60 and over
Trial IDs: CASE4913, NCI-2014-00252, NCT02071901
Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 2012-0920, NCI-2013-02348, NCT01927731
Eltrombopag in MDS Patients with Thrombocytopenia
Phase: Phase I
Type: Supportive care
Age: 18 and over
Trial IDs: MCC-16523, NCI-2011-00784, QR 25807/1, NCT01286038
Eltrombopag Olamine in Increasing Platelet Counts in Patients with Relapsed/Refractory Acute Myeloid Leukemia Undergoing Chemotherapy
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: I 206111, NCI-2012-00215, NCT01550185
Eltrombopag Olamine and Filgrastim in Mobilizing Stem Cells in Patients with Multiple Myeloma Undergoing Peripheral Blood Stem Cell Transplant
Phase: No phase specified
Type: Treatment
Age: 18 to 70
Trial IDs: 10-346, NCI-2011-00899, NCT01286675
Start Over